Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04824092
Title	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)
Acronym	frontMIND
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	MorphoSys AG
Indications	diffuse large B-cell lymphoma follicular lymphoma extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue B-cell lymphoma
Therapies	Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| SVK \| ROU \| POL \| NZL \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| AUT \| AUS \| ARG